MediWound Announces Publication Of The EscharEx Phase II ChronEx Study Results For Venous Leg Ulcers In THE LANCET's eClinicalMedicine
Portfolio Pulse from Benzinga Newsdesk
MediWound Ltd. (NASDAQ:MDWD) announced the publication of Phase II ChronEx study results for EscharEx in treating Venous Leg Ulcers in THE LANCET's eClinicalMedicine. The study shows EscharEx outperforms non-surgical standard care in debridement and promoting healthy granulation tissue.
July 29, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MediWound Ltd. (NASDAQ:MDWD) announced positive Phase II study results for EscharEx, published in THE LANCET's eClinicalMedicine. The study shows EscharEx outperforms non-surgical standard care in treating Venous Leg Ulcers.
The publication of positive Phase II study results in a prestigious journal like THE LANCET's eClinicalMedicine is likely to boost investor confidence in MediWound's product pipeline, potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100